Overall Clinical Benefit Rate of 85%, Partial Response Rate of 42% and Progression Free Survival of 5.4 Months Observed in Patients with > 2 Prior Therapies and/or Prior Bevacizumab
REDWOOD CITY, Calif., Oct. 20, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced interim results from its ongoing Phase 1b trial investigating navicixizumab, OncoMed's anti-DLL4/VEGF bispecific antibody, in combination with paclitaxel in patients with platinum-resistant ovarian cancer.
The interim results were presented at the European Society for Medical Oncology in Munich. The patients had received a median of four prior therapies, all of whom had received prior paclitaxel and 69% had received prior bevacizumab. Twentytwo of the 26 patients (85%) treated with the novel regimen experienced clinical benefit. Notably 11 of the 26 patients (42%) achieved a partial response and the median progression-free survival was 5.4 months (95% CI: 3.5-8.0 months). Historical response rates for patients with heavily pretreated platinum-resistant ovarian cancer treated with chemotherapy are typically 15% or less.
Read More: https://oncomed.gcs-web.com/static-files/ce0dd21c-2466-40d8-85de-2c79d7c0f87d
OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer
Via: Business Wire
GRAND RAPIDS, Mich.--(BUSINESS WIRE)--Today Priority Health announced it will offer a new digital prevention tool to help members manage their diabetes. Through its partnership with Omada Health, Priority Health will provide clinically-eligible members access to Omada, the country’s leading digital Diabetes Prevention Program (DPP), beginning this month. Priority Health is the first health plan in Michigan to add the Centers for Disease Control and Prevention (CDC) fully recognized digital Diabetes Prevention Program as a preventive benefit.